Apnimed, Inc. — Form 8-K
Filed November 16, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 72/100
What the filing says
Apnimed reported Q3 2026 net loss of $29.5M (vs. $10.9M in Q3 2025), with cash position of $351.8M as of September 30, 2026 (up from $41.9M at year-end 2025, following ~$199M IPO proceeds in August 2026). The company's lead candidate AD109 (proposed brand Oxnimbi) for obstructive sleep apnea remains under FDA review with a PDUFA goal date of February 28, 2027; the company is advancing commercial readiness activities and presented five abstracts at CHEST 2026 conference. Operating expenses increased significantly: R&D rose 20% to $11.8M, and G&A more than doubled to $22.6M (driven by professional services, launch infrastructure, and hiring for commercial preparation).
Why this rating
FDA milestone approaching (Feb 2027) for first-in-class OSA therapy; strong cash runway ($351.8M, 180% of company assets); commercial readiness advancing. Material for $195.5M company but regulatory approval remains uncertain.
Tradability signal
NO TRADE
No trade: positive news with no measurable pre-read move — good news prices in within seconds and long-side continuation has shown no measured edge (this cell: -0.43% over 4 hrs, n=488). (Filing arrived outside market hours — evaluated at the next open with a live quote.)
Derived from this site's own measured outcomes + live price/liquidity at analysis time. An experiment, not investment advice.
Price action (we called it positive)
at our read · unknown $16.16 | +10 min · unknown $16.36 ▲ 1.24% | +30 min · unknown $16.08 ▼ 0.50% | +1 hr · unknown $16.47 ▲ 1.92% | +4 hrs · unknown $16.49 ▲ 2.04% |
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from November 16, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.